Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 2/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 2/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | FECH | P22830 | 1/20 | 0.58 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.58 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944351 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL6941915 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL31060723 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL6940188 | 0.94 | PIK3CA (0.88) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| Bicarbonate SCHEMBL1552842 | 0.93 | PIK3CA (0.87) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL13962745 | 0.92 | PIK3CA (0.85) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL593779 | 0.92 | PIK3CA (0.85) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL593778 | 0.92 | PIK3CA (0.85) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL6954638 | 0.91 | PIK3CA (0.84) | PIK3CAMTORPIK3CGPRKDCRICTOR | |
| SCHEMBL13962729 | 0.91 | PIK3CA (0.84) | PIK3CAMTORPIK3CGPRKDCRICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217183-A1 | PREPARED NATURAL KILLER CELLS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | claimed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4355367-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | Barinthus Biotherapeutics North America, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2022266340-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | VACCITECH NORTH AMERICA, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20260027145-A1 | METHODS OF TRANSDUCTION USING A VIRAL VECTOR AND INHIBITORS OF ANTIVIRAL RESTRICTION FACTORS | SANA BIOTECHNOLOGY, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025217183-A1 | PREPARED NATURAL KILLER CELLS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-20110015197-A1 | mTOR INHIBITOR SALT FORMS | OSI PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015197-A1 | mTOR INHIBITOR SALT FORMS | OSI PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | PIK3CA 3890/4885MTOR 3655/4885PIK3CG 4451/4885 |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | PIK3CA 25/4885MTOR 1/4885PIK3CG 142/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | PIK3CA 3890/4885MTOR 3711/4885PIK3CG 4443/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | PIK3CA 57/4885MTOR 5/4885PIK3CG 360/4885 |
| US-20260027145-A1 | METHODS OF TRANSDUCTION USING A VIRAL VECTOR AND INHIBITORS OF ANTIVIRAL RESTRICTION FACTORS | RICTOR, MAVS, FUS | PIK3CA 969/4885MTOR 4/4885PIK3CG 966/4885 |
| US-20110015197-A1 | mTOR INHIBITOR SALT FORMS | MTOR, RPTOR, RICTOR | PIK3CA 64/4885MTOR 1/4885PIK3CG 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.